Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Pfizer

Status: Completed

Conditions: Kidney Transplantation

Treatments: Drug: Tofacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT01375127

A3921053

Details and patient eligibility

About

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

Full description

Subjects are identified based on whether they received tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or who did not elect to enroll in long-term extension studies. Subjects are pre-identified

Enrollment: 83 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects have discontinued tofacitinib prior to the planned treatment duration in 2 completed Phase 2 studies; or have not enrolled in long-term extension studies.

Exclusion criteria

• No other subjects are eligible for this study

Trial design

83 participants in 2 patient groups

Subjects from Study A3921009

Treatment:

Drug: Tofacitinib

Subjects from Study A3921030

Treatment:

Drug: Tofacitinib